EQRx was a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2020 by Alexis Borisy with a mission to develop and deliver innovative, patent-protected medicines at radically lower prices. The company went public in 2021 through a SPAC merger with CM Life Sciences III and built an oncology and immunology pipeline anchored by in-licensed candidates such as aumolertinib and sugemalimab. In 2023 EQRx wound down its drug-development programs and was acquired by Revolution Medicines in an all-stock transaction. It was surfaced in the API Evangelist network as a portfolio-company lead (backed by a16z and GV); it never operated a public developer platform or API, and its web presence is no longer live.
EQRx is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Pharmaceuticals, Biotechnology, and Oncology.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/eqrx: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: eqrx
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source: []
generated: '2026-07-22'
method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/eqrx.png
name: EQRx
description: EQRx was a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2020 by Alexis Borisy with
a mission to develop and deliver innovative, patent-protected medicines at radically lower prices. The company went public
in 2021 through a SPAC merger with CM Life Sciences III and built an oncology and immunology pipeline anchored by in-licensed
candidates such as aumolertinib and sugemalimab. In 2023 EQRx wound down its drug-development programs and was acquired
by Revolution Medicines in an all-stock transaction. It was surfaced in the API Evangelist network as a portfolio-company
lead (backed by a16z and GV); it never operated a public developer platform or API, and its web presence is no longer live.
url: https://raw.githubusercontent.com/api-evangelist/eqrx/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
- gv
x-tier: stub
x-tier-reason: portfolio-lead
x-status: defunct
x-status-note: Acquired by Revolution Medicines (2023); drug-development wound down; no live developer surface.
x-headquarters: Cambridge, Massachusetts, United States
x-founded: '2020'
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-09-15'
tags:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Biotechnology
- Oncology
- Drug Development
- Life Sciences
- Healthcare
- Defunct
common:
- type: DomainSecurity
url: security/eqrx-domain-security.yml
- type: Website
url: https://eqrx.com
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
x-enrichment:
date: '2026-07-19'
status: backfilled
pass: local-v1
note: backfilled from .gitignore signal + verified work evidence
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →